Updates on HER2-Directed ADCs Across Solid Tumors

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.